EP0536401A1 - Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same - Google Patents

Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same

Info

Publication number
EP0536401A1
EP0536401A1 EP91911075A EP91911075A EP0536401A1 EP 0536401 A1 EP0536401 A1 EP 0536401A1 EP 91911075 A EP91911075 A EP 91911075A EP 91911075 A EP91911075 A EP 91911075A EP 0536401 A1 EP0536401 A1 EP 0536401A1
Authority
EP
European Patent Office
Prior art keywords
hydroxy
alkyl
compound
aryl
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP91911075A
Other languages
German (de)
French (fr)
Inventor
Chiyoshi Kasahara
Takehiko Ohkawa
Masashi Hashimoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Publication of EP0536401A1 publication Critical patent/EP0536401A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Definitions

  • This invention relates to novel tricyclo compounds having pharmacological activities, to a process for their production and to a pharmaceutical composition containing the same.
  • novel tricyclo compounds which have pharmacological activities such as immunosuppressive activity, antimicrobial activity, and the like, to a process for their production, to a
  • composition containing the same and to a use thereof as a medicament.
  • one object of this invention is to provide the novel tricyclo compounds, which are useful for treatment and prevention of resistance by transplantation, graft-versus-host diseases by medulla ossium
  • Another object of this invention is to provide a process for production of the tricyclo compounds by
  • a further object of this invention is to provide a pharmaceutical composition containing, as active
  • Still further object of this invention is to provide a use of the tricyclo compounds as a medicament for treating and preventing resistance by transplantation, graft-versus-host diseases by medulla ossium
  • R 1 is hydrogen or acyl
  • R 2 is hydrogen, hydroxy, alkoxy or acyloxy
  • R 3 is (C 3 -C 7 )alkyl, aryl(C 2 -C 7 ) alkyl, protected carboxy ( C 2 -C 7 ) alkyl, 1-(C 3 -C 7 )alkenyl, aryl-1-(C 2 -C 7 )alkenyl or protected
  • R 4 is hydroxy or alkoxy
  • R 5 is hydrogen and R 6 is hydroxy or methoxy, or R 5 and R 6 are combined to form oxo,
  • A is methylene, hydroxymethylene or carbonyl, n is an integer of 1 or 2, and
  • the object tricyclo compounds (I) can be prepared by the following processes in which R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , A and n are each as defined above,
  • R 7 is (C 2 -C 6 ) alkyl, aryl(C 1 -C 8 )alkyl or protected carboxy(C 1 -C 6 )alkyl,
  • R 8 is aryl
  • R 9 is protected carboxy
  • R 10 is (C 2 -C 8 )alkylidene, aryl(C 1 -C 8 )alkylidene or protected carboxy(C 1 -C 8 )alkylidene, and
  • X is halogen
  • Suitable "acyl” and acyl group in the “acyloxy” may include aliphatic acyl, aromatic acyl and aliphatic acyl substituted with aromatic group, which are derived from carboxylie, sulfonic and carbamic acids; and the like.
  • the aliphatic acyl may include lower alkanoyl which may have one or more suitable substituent(s) such as carboxy (e.g. formyl, acetyl, propionyl, butyryl,
  • camphorsulfonyl lower alkylcarbamoyl having one or more suitable substituent(s) such as carboxy, protected carboxy and hydroxy for example, carboxy(lower) alkylcarbamoyl (e.g. carboxymethylcarbamoyl, carboxyethylcarbamoyl, carboxypropylcarbamoyl, carboxybutylcarbamoyl,
  • hydroxy(lower)alkylcarbamoyl e.g. hydroxymethylcarbamoyl, hydroxyethylcarbamoyl, hydroxypropylcarbamoyl,
  • the aromatic acyl may include aroyl which may have one or more suitable substituent(s) such as nitro (e.g. benzoyl, toluoyl, xyloyl, naphthoyl, nitrobenzoyl,
  • suitable substituent(s) such as nitro (e.g. benzoyl, toluoyl, xyloyl, naphthoyl, nitrobenzoyl,
  • dinitrobenzoyl, nitronaphthoyl, etc. arenesulfonyl which may have one or more suitable substituent(s) such as halogen (e.g. benzenesulfonyl, toluenesulfonyl,
  • arylcarbamoyl which may have one or more suitable
  • substituent(s) such as halogen (e.g. phenylcarba-moyl, fluorophenylcarbamoyl, chlorophenylcarbamoyl, etc.), and the like.
  • halogen e.g. phenylcarba-moyl, fluorophenylcarbamoyl, chlorophenylcarbamoyl, etc.
  • the heterocyclic acyl may include heterocyclic carbonyl (e.g. furoyl, thenoyl, nicotinoyl, isonicotinoyl, thiazolylcarbonyl, thiadiazolylcarbonyl,
  • heterocyclic carbonyl e.g. furoyl, thenoyl, nicotinoyl, isonicotinoyl, thiazolylcarbonyl, thiadiazolylcarbonyl
  • the aliphatic acyl substituted with aromatic group may include ar(lower) alkanoyl which may have one or more suitable substituent(s) such as lower alkoxy and
  • trihalo(lower) alkyl e.g. phenylacetyl, phenylpropionyl, phenylbutyryl, 2-trifluoromethyl-2-methoxy-2-phenylacetyl, 2-ethyl-2-trifluoromethyl-2-phenylacetyl, 2-trifluoro-methyl-2-propoxy-2-phenylacetyl, etc.
  • lower alkyl e.g. phenylacetyl, phenylpropionyl, phenylbutyryl, 2-trifluoromethyl-2-methoxy-2-phenylacetyl, 2-ethyl-2-trifluoromethyl-2-phenylacetyl, 2-trifluoro-methyl-2-propoxy-2-phenylacetyl, etc.
  • the more preferred acyl group thus defined may be C 1 -C 4 alkanoyl which may have carboxv, cyclo(C 5 -C 6 )- alkyloxy(C 1 -C 4 ) alkanoyl having two (C 1 -C 4 ) alkyl groups on the cycloalkyl moiety, camphorsulfonyl, carboxy(C 1 -C 4 )- alkylcarbamoyl, hydroxy(C 1 -C 4 )alkylcarbamoyl,
  • menthyloxyacetyl camphorsulfonyl, hydroxypropylcarbamoyl, benzoyl, nitrobenzoyl, dinitrobenzoyl,
  • Suitable alkoxy may be lower alkoxy such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, pentoxy, isopentoxy, neopentoxy, hexyloxy and the like, in which the preferred one is C 1 -C 4 alkoxy.
  • Suitable "(C 3 -C 7 )alkyl” may include straight or branched one such as propyl, isopropyl, butyl, isobutyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, and the like, in which more preferred example may be (C 3 -C 5 )alkyl and the most preferred one may be propyl and pentyl.
  • Suitable "(C 2 -C 6 ) alkyl” may include straight or branched one such as ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, isopentyl, neopentyl, hexyl, and the like, in which more preferred example may be (C 2 -C 4 ) alkyl and the most preferred one may be ethyl and butyl.
  • Suitable "aryl(C 2 -C 7 ) alkyl” may include
  • Suitable "protected carboxy(C 2 -C 7 ) alkyl” may include aforementioned (C 3 -C 7 )alkyl and ethyl, which is
  • Suitable "1-(C 3 -C 7 ) alkenyl” may include straight or branched one such as 1-propenyl, 1-isopropenyl, 1-butenyl, 1-isobutenyl, 1-pentenyl, 1-isopentenyl, 1-neopentenyl, 1-hexenyl, 1-heptenyl, and the like, in which more
  • preferred example may be 1-(C 3 -C 5 ) alkenyl and the most preferred one may be 1-propenyl and 1-pentenyl.
  • Suitable "aryl-1-(C 2 -C 7 ) alkenyl” may include
  • Suitable "protected carboxy-1-(C 2 -C 7 ) alkenyl” may include aforementioned 1-(C 3 -C 7 ) alkenyl and ethenyl, which is substituted with protected carboxy as mentioned below, wherein more preferred example may be
  • Suitable "aryl(C 1 -C 8 ) alkyl” may include straight or branched one such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, isopentyl, neopentyl, hexyl, and the like, which is substituted with aryl as mentioned below, wherein more preferred example may be
  • Suitable "protected carboxy(C 1 -C 8 ) alkyl” may include straight or branched one such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, isopentyl, neopentyl, hexyl, and the like, which is substituted with protected carboxy as mentioned below, wherein more preferred example may be (C 1 -C 4 )alkoxycarbonyl(C 1 -C 4 )alkyl.
  • Suitable "(C 2 -C 6 )alkylidene” may include straight or branched one such as ethylidene, propylidene,
  • (C 2 -C 4 )alkylidene and the most preferred one may be ethylidene and butylidene.
  • Suitable "aryl(C 1 -C 8 )alkylidene” may include
  • Suitable "protected carboxy(C 1 -C 8 )alkylidene” may include aforementioned (C 2 -C 6 )alkylidene and methylene, which are substituted with protected carboxy as mentioned below, wherein more preferred example may be (C 1 -C 4 )alkoxycarbonyl(C 1 -C 4 )alkylidene and the most preferred one may be methoxycarbonylmethylene.
  • Suitable “leaving group” may include an acid residue and the like, and suitable examples of “acid residue” may be halogen (e.g. chlorine, bromine, iodine, etc.), sulfonyloxy (e.g. methanesulfonyloxy, benzenesulfonyloxy, toluenesulfonyloxy, etc.) or the like.
  • Suitable “protected carboxy” may include esterified carboxy such as lower alkoxycarbonyl (e.g.
  • Suitable "aryl” may include phenyl, tolyl, xylyl, cumenyl, mesityl, naphthyl, and the like, in which the preferred example may be phenyl.
  • Suitable "halogen” may be chlorine bromine, fluorine and iodine, in which the preferred one may be chlorine and bromine.
  • the compound (Ia) or a salt thereof can be prepared by hydroxylating the compound ( II ) or a salt thereof.
  • the hydroxylating agent applicable to this process may be a conventional one which is capable of introducing hydroxy group(s) into the allyl moiety of starting
  • compound (II) for example, alkali metal permanganate (e.g. potassium permanganate, etc.), osmium tetroxide optionally in the presence of a suitable oxidizing agent to regenerate osmium tetroxide (e.g. N-methylmorpholine N-oxide, sodium chlorate, etc.), hydrogen peroxide, and the like.
  • alkali metal permanganate e.g. potassium permanganate, etc.
  • osmium tetroxide optionally in the presence of a suitable oxidizing agent to regenerate osmium tetroxide (e.g. N-methylmorpholine N-oxide, sodium chlorate, etc.), hydrogen peroxide, and the like.
  • This reaction is usually conducted in a conventional solvent which does not adversely influence the reaction such as water, methanol, ethanol, propanol, pyridine, ethyl acetate, N,N-dimethylformamide, dichloromethane, ethyl ether, isopropyl ether, 1,4-dioxane or a mixture thereof.
  • a conventional solvent which does not adversely influence the reaction
  • the reaction temperature of this reaction is not critical and the reaction is usually conducted under from cooling to warming.
  • the compound (lb) or a salt thereof can be prepared by oxidizing the compound (la) or a salt thereof to an aldehyde.
  • the oxidizing agent applicable to this process may be a conventional one which is capable of oxidizing vicinal diols to an aldehyde, for example, perhalogenic acid or a salt thereof (e.g. periodic acid, sodium metaperiodate, etc.), lead tetra(lower alkanoate) (e.g. lead
  • This reaction is usually conducted in a conventional solvent which does not adversely influence the reaction such as water, methanol, ethanol, propanol, pyridine, ethyl acetate, N,N-dimethylformamide, dichloromethane, ethyl ether, isopropyl ether, 1,4-dioxane, or a mixture thereof.
  • a conventional solvent which does not adversely influence the reaction such as water, methanol, ethanol, propanol, pyridine, ethyl acetate, N,N-dimethylformamide, dichloromethane, ethyl ether, isopropyl ether, 1,4-dioxane, or a mixture thereof.
  • the reaction temperature is not critical and the reaction is usually conducted under from cooling to warming.
  • the compound (Ic) or a salt thereof can be prepared by reacting the compound (lb) or a salt thereof with the compound (IlIa) or (Illb).
  • this reaction can preferably be carried out in the presence of an organic or inorganic base such as lower alkylalkalimetal (e.g. methyllithium, butyllithium, etc.), alkali metal (e.g. lithium, sodium, potassium, etc.), alkaline earth metal (e.g. calcium, etc.), alkali metal hydride (e.g. sodium hydride, etc.), alkaline earth metal hydride (e.g. calcium hydride, etc.), alkali metal
  • hydroxide e.g. sodium hydroxide, potassium hydroxide, etc.
  • alkali metal carbonate e.g. sodium carbonate, potassium carbonate, etc.
  • alkali metal hydrogen e.g. sodium hydroxide, potassium hydroxide, etc.
  • alkali metal alkoxide e.g. sodium methoxide, sodium ethoxide, potassium
  • alkali metal alkanoic acid e.g. sodium acetate, etc.
  • trialkylamine e.g. triethylamine, etc.
  • pyridine compound e.g. pyridine, lutidine, picoline, 4-N,N-dimethylaminopyridine, etc.
  • guinoline and the like.
  • the reaction is usually conducted in a conventional solvent which does not adversely influence the reaction such as acetone, dichloromethane, alcohol (e.g. methanol, ethanol, etc.), tetrahydrofuran, pyridine, benzene,
  • the reaction temperature is not critical and the reaction is usually conducted under from cooling to warming.
  • the compound (Id) or a salt thereof can be prepared by reducing the compound (Ic) or a salt thereof.
  • the reduction method applicable for this reaction is a conventional one which is capable of hydrogenating olefinic bond and may include, for example, reduction by using a combination of a metal (e.g. zinc, zinc amalgam, etc.) or a chrome compound (e.g. chromous chloride, chromous acetate, etc.) and an organic or inorganic acid (e.g. acetic acid, prop ⁇ onic acid, hydrochloric acid, sulfuric acid, etc.); and conventional catalytic reduction in the presence of a conventional metallic catalyst such as palladium catalysts (e.g.
  • solvent which does not adversely influence the reaction
  • water alcohol (e.g. methanol, ethanol, propanol, etc.), dioxane, tetrahydrofuran, acetic acid, buffer solution (e.g. phosphate buffer, acetate buffer, etc.), benzene, toluene, xylene, and the like, or a mixture thereof.
  • alcohol e.g. methanol, ethanol, propanol, etc.
  • dioxane etrahydrofuran
  • acetic acid e.g. phosphate buffer, acetate buffer, etc.
  • buffer solution e.g. phosphate buffer, acetate buffer, etc.
  • benzene toluene
  • xylene e.g. benzene, toluene, xylene, and the like, or a mixture thereof.
  • the reaction temperature is not critical and the reaction is usually carried out under from cooling to warming.
  • the object tricyclo compounds (I), obtained according to the processes as explained above can be isolated and purified in a conventional manner, for example,
  • Suitable salts of the compounds (I), (la), (lb), (Ic), (Id) and (II) may include pharmaceutically
  • salts such as basic salts, for example, alkali metal salt (e.g. sodium salt, potassium salt, etc.), alkaline earth metal salt (e.g. calcium salt, magnesium salt, etc.), ammonium salt, amine salt (e.g. triethylamine salt, N-benzyl-N-methylamine salt, etc.) and other salts.
  • alkali metal salt e.g. sodium salt, potassium salt, etc.
  • alkaline earth metal salt e.g. calcium salt, magnesium salt, etc.
  • ammonium salt e.g. triethylamine salt, N-benzyl-N-methylamine salt, etc.
  • amine salt e.g. triethylamine salt, N-benzyl-N-methylamine salt, etc.
  • the starting compound (II) in the process mentioned above contains known and novel compounds, and the known compounds are disclosed, for example, in European Patent Publication Nos. 184162 and 323042 and the new compound can be prepared by a conventional manner.
  • the tricyclo compounds (I) possess pharmacological activities such as immunosuppressive activity,
  • immunosuppressant such as the resistance by transplantation of organs or tissue such as heart, kidney, liver, medulla ossium, skin, cornea, lung, pancreas, intestinum ***, limb, muscle, nervus, etc.;
  • autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's
  • thyroiditis multiple sclerosis, myasthenia gravis, type I diabetes, and the like; and further infectious diseases caused by pathogenic microorganisms.
  • tricyclo compounds (I) are also useful for the treatment and the prophylaxis of inflammatory and hyperproliferative skin diseases and cutaneous
  • immunologically-mediated illnesses such as, psoriasis, atopical dermatitis, contact dermatitis and further eczematous dermatitises, seborrhoeis dermatitis, Lichen planus, Pemphigus; bullous Pemphigoid, Epidermolysis bullosa, urticaria, angioedemas, vasculitides, erythemas, cutaneous e ⁇ sinophilias, Lupus erythematosus, acne and Alopecia areata;
  • autoimmune diseases e.g. keratoconjunctivitis, vernal conjunctivitis, uveitis associated with Behcet's disease, keratitis, herpetic keratitis, conical cornea, dystrophia epithelialis corneae, corneal leukoma, ocular pemphigus, Mooren's ulcer,
  • reversible obstructive airways disease which includes conditions such as asthma (e.g. bronchial asthma, allergic asthma, intrinsic asthma, extrinsic asthma and dust asthma
  • asthma e.g. bronchial asthma, allergic asthma, intrinsic asthma, extrinsic asthma and dust asthma
  • chronic or inveterate asthma e.g. late asthma and airway hyper-responsiveness
  • bronchitis e.g. chronic or inveterate asthma and the like
  • inflammation of mucosa and blood vessels such as gastric ulcers, vascular damage caused by ischemic diseases and thrombosis, ischemic bowel disease, inflammatory bowel disease, necrotizing enterocolitis, intestinal lesions associated with thermal burns, leukotriene B 4 -mediated diseases;
  • intestinal inflammations/allergies such as Coeliac disease, proctitis, eosnophilic gastroenteritis, mastocytosis,
  • renal diseases selected from interstitial nephritis,
  • nervous diseases selected from multiple myositis
  • endocrine diseases selected from hyperthyroidism and
  • hematic diseases selected from pure red cell aplasia, aplastic anemia, hypoplastic anemia, idiopathic
  • thrombocytopenic purpura autoimmune hemolytic anemia, agranulocytosis and anerythroplasia
  • bone diseases such as osteoporosis
  • respiratory diseases selected from sarcoidosis, fibroid lung and idiopathic interstitial pneumonia; skin diseases selected from dermatomyositis, leukoderma vulgaris, ichthyosis vulgaris, photoallergic sensitivity and cutaneous T cell lymphoma;
  • circulatory diseases selected from arteriosclerosis, atherosclerosis, aortitis syndrome, polyarteritis nodosa and myocardosis;
  • collagen diseases selected from scleroderma, Wegener's granuloma and Sjogren's syndrome;
  • nephrotic syndrome such as glomerulonephritis
  • the tricyclo compounds (I) have liver regenerating activity and/or activities of stimulating hypertrophy and hyperplasia of hepatocytes. Therefore, they are useful for the treatment and prevention of hepatic diseases such as immunogenic diseases (e.g. chronic hepatic diseases).
  • autoimmune liver diseases selected from the group consistin of autoimmune hepatitis, primary biliary cirrhosis and sclerosing cholangitis), partial liver resection, acute liver necrosis (e.g. necrosis caused by toxins, viral hepatitis, shock or anoxia), B-virus hepatitis, non-A/non-B hepatitis and cirrhosis.
  • tricyclo compounds (I) are useful for various diseases because of its useful pharmaceutical activity such as augmenting activity of chemotherapeutic effect.
  • the MLR test was performed in microtiter plates, with each well containing 5 ⁇ 10 5 C57BL/6 responder cells
  • 1640 medium supplemented with 10% fetal calf serum, 2mM sodium bicarbonate, penicillin (50 unit/ml) and
  • streptomycin 50 ⁇ g/ml.
  • the cells were incubated at 37°C in humidified atmosphere of 5% carbon dioxide and 95% of air for 68 hours and pulsed with 3 H-thymidine (0.5 ⁇ Ci) 4 hours before the cells were collected.
  • 3 H-thymidine 0.5 ⁇ Ci
  • the IC 50 value (mol concentration to suppress 50% of MLR) was calculated by a conventional method, which is shown in the following Table 1.
  • composition of this invention can be used in the form of a pharmaceutical preparation, for example, in solid, semisolid or liquid form, which
  • the active ingredient in admixture with an organic or inorganic carrier or excipient suitable for external, enteral or parenteral applications.
  • the active ingredient may be compounded, for example, with the usual non-toxic,
  • the carriers which can be used are water, glucose,
  • lactose lactose
  • gum acacia gelatin
  • mannitoi starch paste
  • magnesium trisilicate magnesium trisilicate
  • talc corn starch
  • keratin
  • colloidal silica, potato starch, urea and other carriers suitable for use in manufacturing preparations, in solid, semisolid, or liquid form, and in addition auxiliary, stabilizing, thickening, solubilizing and coloring agents and perfumes may be used.
  • a solubilizing agent there may be exemplified water-soluble cellulose polymer (i.e. hydroxypropyl methylcellulose, etc.), water-soluble glycol (i.e. propylene glycol, etc.), etc.
  • the active object compound is included in the
  • composition in an amount, sufficient to produce the desired effect upon the process or condition of diseases.
  • a daily dose of about 0.01-1000 mg, preferably 0.1-500 mg and more preferably 0.5-100 mg, of the active ingredient is generally given for treating diseases, and an average single dose of about 0.5 mg, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg, 250 mg and 500 mg is generally administered.
  • a daily dose of about 0.01-1000 mg, preferably 0.1-500 mg and more preferably 0.5-100 mg, of the active ingredient is generally given for treating diseases, and an average single dose of about 0.5 mg, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg, 250 mg and 500 mg is generally administered.
  • n-butyltriphen ⁇ lphosphonium bromide (505 mg) in diethyl ether (9.2 ml) at 0°C was added 1.4 M methyllithium in hexane (0.9 ml). The orange reaction mixture was warmed to room temperature and stirred for 2 hours.

Abstract

L'invention concerne des composés de la formule (I), dans laquelle R1 représente hydrogène ou acyle, R2 représente hydrogène, hydroxy, alcoxy ou acyloxy, R3 est (C3-C7)alkyle, aryl(C2-C7), carboxy(C2-C7)alkyle protégé, 1-(C3-C7)alcényle, aryl-1-(C2-C7)alcényle, R4 représente hydroxy ou alcoxy, R5 représente hydrogène et R6 est hydroxy ou méthoxy ou bien R5 et R6 sont combinés pour former oxo, A représente méthylène, hydroxyméthylène ou carbonyle, n est un nombre entier valant 1 ou 2, et le symbole constitué d'une ligne et d'une ligne en pointillé représente une liaison simple ou double. L'invention concerne aussi des sels de ces composés, des procédés de production desdits composés ainsi que des compositions pharmaceutiques contenant ces composés.The invention relates to compounds of formula (I), in which R1 represents hydrogen or acyl, R2 represents hydrogen, hydroxy, alkoxy or acyloxy, R3 is (C3-C7) alkyl, aryl (C2-C7), carboxy (C2 -C7) protected alkyl, 1- (C3-C7) alkenyl, aryl-1- (C2-C7) alkenyl, R4 represents hydroxy or alkoxy, R5 represents hydrogen and R6 is hydroxy or methoxy or R5 and R6 are combined to form oxo, A represents methylene, hydroxymethylene or carbonyl, n is an integer equal to 1 or 2, and the symbol consisting of a line and a dotted line represents a single or double bond. The invention also relates to salts of these compounds, processes for the production of said compounds as well as pharmaceutical compositions containing these compounds.

Description

DESCRIPTION
TRICYCLO COMPOUNDS, A PROCESS FOR THEIR PRODUCTION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
This invention relates to novel tricyclo compounds having pharmacological activities, to a process for their production and to a pharmaceutical composition containing the same.
More particularly, it relates to novel tricyclo compounds, which have pharmacological activities such as immunosuppressive activity, antimicrobial activity, and the like, to a process for their production, to a
pharmaceutical composition containing the same and to a use thereof as a medicament.
Accordingly, one object of this invention is to provide the novel tricyclo compounds, which are useful for treatment and prevention of resistance by transplantation, graft-versus-host diseases by medulla ossium
transplantation, autoimmune diseases, infectious diseases, and the like. Another object of this invention is to provide a process for production of the tricyclo compounds by
synthetic process.
A further object of this invention is to provide a pharmaceutical composition containing, as active
ingredients, the tricyclo compounds.
Still further object of this invention is to provide a use of the tricyclo compounds as a medicament for treating and preventing resistance by transplantation, graft-versus-host diseases by medulla ossium
transplantation, autoimmune diseases, infectious diseases, and the like.
European Patent Application 184162 (Fujisawa
Pharmaceutical Co. Ltd.) discloses a number of macrccyclic compounds isolated from microorganisms belonging to genus Streptomyces such as Streptomyces tsukubaensis No. 3993 (FERM BP-927) and Streptomyces hyqroscopicus subsp.
yakushimaensis No. 7238 (FERM BP-928). Such macrclides are particularly numbered FR-900505, FR-900520,
FR-900523 and FR-900525. And the preparation of some their derivatives is also described.
International Patent Application WO 89/05304, European Patent Application Nos. 353678, 349049, 349061, 356399, 402931, etc also disclose a number of macrocyclic immunosuppressive compounds.
We have now found a novel group of compounds which possess certain advantageous properties over those
disclosed previousIy. Thus, according to the invention, we provide a new compound of the following formula:
(continued on the next page)
wherein R1 is hydrogen or acyl,
R2 is hydrogen, hydroxy, alkoxy or acyloxy,
R3 is (C3-C7)alkyl, aryl(C2-C7) alkyl, protected carboxy ( C2-C7) alkyl, 1-(C3-C7)alkenyl, aryl-1-(C2-C7)alkenyl or protected
carboxy-1-(C7-C7)alkenyl,
R 4 is hydroxy or alkoxy,
R5 is hydrogen and R6 is hydroxy or methoxy, or R5 and R6 are combined to form oxo,
A is methylene, hydroxymethylene or carbonyl, n is an integer of 1 or 2, and
the symbol of a line and dotted line is a single bond or a double bond.
With respect to the tricyclo compounds (I) of this invention, it is to be understood that there may be one or more conformerl(s) or stereoisomeric pairs such as optical and geometrical isomers due to asymmetric carbon atom(s) and double bond(s), and such isomers are also included within a scope of this invention.
According to this invention, the object tricyclo compounds (I) can be prepared by the following processes in which R1, R2, R3, R4, R5, R6, A and n are each as defined above,
R7 is (C2-C6) alkyl, aryl(C1-C8)alkyl or protected carboxy(C1-C6)alkyl,
R8 is aryl,
R9 is protected carboxy,
R10 is (C2-C8)alkylidene, aryl(C1-C8)alkylidene or protected carboxy(C1-C8)alkylidene, and
X is halogen.
Particulars of the above definitions and the preferred embodiments thereof are explained in detail as follows.
The term "lower" used in the specification is
intended to mean 1 to 6 carbon atoms, unless otherwise indicated.
Suitable "acyl" and acyl group in the "acyloxy" may include aliphatic acyl, aromatic acyl and aliphatic acyl substituted with aromatic group, which are derived from carboxylie, sulfonic and carbamic acids; and the like.
The aliphatic acyl may include lower alkanoyl which may have one or more suitable substituent(s) such as carboxy (e.g. formyl, acetyl, propionyl, butyryl,
isobutyryi, valeryl, isovaleryl, pivaioyl, hexanoyl, carboxyacetyl, carboxypropionyl, carboxybutyryl,
carboxyhexanoyl, etc.), cyclo(lower)alkyloxy(lower)- alkanoyl which may have one or more suitable
substituent(s) such as lower alkyl (e.g.
cyclopropyloxyacetyl, cyclobutyloxypropionyl,
cycloheptyloxybutyryl, menthyloxyacetyl,
menthyloxypropionyl, menthyloxybutyryl,
menthyloxyheptanoyl, menthyloxyhexanoyl, etc.),
camphorsulfonyl, lower alkylcarbamoyl having one or more suitable substituent(s) such as carboxy, protected carboxy and hydroxy for example, carboxy(lower) alkylcarbamoyl (e.g. carboxymethylcarbamoyl, carboxyethylcarbamoyl, carboxypropylcarbamoyl, carboxybutylcarbamoyl,
carboxypentylcarbamoyl, carboxyhexylcarbamoyl, etc.), protected carboxy(lower) alkylcarbamoyl such as tri(lower)alkylsilyl(lower)alko(ycarbonyl(lower)alkylcarbamoyl (e.g. trimethylsilylmethoxycarbonylethylcarbamoyl,
trimethylsilylethoxycarbonylpropylcarbamoyl,
triethylsilylethoxycarbonylpropylcarbamoyl,
tert-butyldimethylsilylethoxycarbonylpropylcarbamoyl,trimethylsilylpropoxycarbonylbutylcarbamoyl, etc.), hydroxy(lower)alkylcarbamoyl (e.g. hydroxymethylcarbamoyl, hydroxyethylcarbamoyl, hydroxypropylcarbamoyl,
hydroxybutylcarbamoyl, hydroxypentylcarbamoyl,
hydroxyhexylcarbamoyl, etc.), and the like.
The aromatic acyl may include aroyl which may have one or more suitable substituent(s) such as nitro (e.g. benzoyl, toluoyl, xyloyl, naphthoyl, nitrobenzoyl,
dinitrobenzoyl, nitronaphthoyl, etc.), arenesulfonyl which may have one or more suitable substituent(s) such as halogen (e.g. benzenesulfonyl, toluenesulfonyl,
xylenesulfonyl, naphthalenesulfonyl,
fluorobenzenesulfonyl, chlorobenzenesulfonyl,
bromobenzenesulfonyl, iodobenzenesuifonyl, etc.),
arylcarbamoyl which may have one or more suitable
substituent(s) such as halogen (e.g. phenylcarba-moyl, fluorophenylcarbamoyl, chlorophenylcarbamoyl, etc.), and the like.
The heterocyclic acyl may include heterocyclic carbonyl (e.g. furoyl, thenoyl, nicotinoyl, isonicotinoyl, thiazolylcarbonyl, thiadiazolylcarbonyl,
tetrazolylcarbonyl, morpholinocarbonyl, etc.), and the like. The aliphatic acyl substituted with aromatic group may include ar(lower) alkanoyl which may have one or more suitable substituent(s) such as lower alkoxy and
trihalo(lower) alkyl (e.g. phenylacetyl, phenylpropionyl, phenylbutyryl, 2-trifluoromethyl-2-methoxy-2-phenylacetyl, 2-ethyl-2-trifluoromethyl-2-phenylacetyl, 2-trifluoro-methyl-2-propoxy-2-phenylacetyl, etc.), and the like.
The more preferred acyl group thus defined may be C1-C4alkanoyl which may have carboxv, cyclo(C5-C6)- alkyloxy(C1-C4) alkanoyl having two (C1-C4) alkyl groups on the cycloalkyl moiety, camphorsulfonyl, carboxy(C1-C4)- alkylcarbamoyl, hydroxy(C1-C 4)alkylcarbamoyl,
tri (C1-C4)alkylsilyl(C1-C4)alkoxycarbonyl(C 1-C4)alkylcarbamoyl, haloarylcarbamoyl, benzoyl which may have one or two nitro, benzenesulfonyl having halogen,
phenyl(C1-C4) alkanoyl having C1-C4alkoxy and
trihalo(C1-C4) alkyl, morpholinocarbonyl, and the most preferred one may be acetyl, carboxypropionyl,
menthyloxyacetyl, camphorsulfonyl, hydroxypropylcarbamoyl, benzoyl, nitrobenzoyl, dinitrobenzoyl,
iodobenzenesulfonyl, phenyϊcarbamoyl,
fluorophenylcarbamoyl, chlorophenylcarbamoyl,
2-trifluoromethyl-2-methoxy-2-phenylacetyl and
morpholinocarbonyl.
Suitable alkoxy may be lower alkoxy such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, pentoxy, isopentoxy, neopentoxy, hexyloxy and the like, in which the preferred one is C1-C4alkoxy.
Suitable "(C3-C 7)alkyl" may include straight or branched one such as propyl, isopropyl, butyl, isobutyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, and the like, in which more preferred example may be (C3-C5)alkyl and the most preferred one may be propyl and pentyl.
Suitable "(C2-C6) alkyl" may include straight or branched one such as ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, isopentyl, neopentyl, hexyl, and the like, in which more preferred example may be (C2-C4) alkyl and the most preferred one may be ethyl and butyl. Suitable "aryl(C2-C7) alkyl" may include
aforementioned (C3-C7) alkyl and ethyl, which are
substituted with aryl as mentioned below, wherein more preferred example may be phenyl(C2-C4) alkyl and the most preferred one may be 2-phenylethyl. Suitable "protected carboxy(C2-C7) alkyl" may include aforementioned (C3-C7)alkyl and ethyl, which is
substituted with protected carboxy as mentioned below, wherein more preferred example may be
(C1-C4)alkoxycarbonyl(C2-C4) alkyl and the most preferred one may be 2-methoxycarbonylethyl.
Suitable "1-(C3-C7) alkenyl" may include straight or branched one such as 1-propenyl, 1-isopropenyl, 1-butenyl, 1-isobutenyl, 1-pentenyl, 1-isopentenyl, 1-neopentenyl, 1-hexenyl, 1-heptenyl, and the like, in which more
preferred example may be 1-(C3-C5) alkenyl and the most preferred one may be 1-propenyl and 1-pentenyl.
Suitable "aryl-1-(C2-C7) alkenyl" may include
aforementioned 1-(C3-C7) alkenyl and ethenyl, which are substituted with aryl as mentioned below, wherein more preferred example may be phenyl-1-(C2-C4) alkenyl and the most preferred one may be 2-phenylethenyl. Suitable "protected carboxy-1-(C2-C7) alkenyl" may include aforementioned 1-(C3-C7) alkenyl and ethenyl, which is substituted with protected carboxy as mentioned below, wherein more preferred example may be
(C1-C4)alkoxycarbonyl-1-(C2-C4) alkenyl and the most preferred one may be 2-methoxycarbonylethenyl.
Suitable "aryl(C1-C8) alkyl" may include straight or branched one such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, isopentyl, neopentyl, hexyl, and the like, which is substituted with aryl as mentioned below, wherein more preferred example may be
phenyl(C1-C4) alkyl and the most preferred one may be benzyl.
Suitable "protected carboxy(C1-C8) alkyl" may include straight or branched one such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, isopentyl, neopentyl, hexyl, and the like, which is substituted with protected carboxy as mentioned below, wherein more preferred example may be (C1-C4)alkoxycarbonyl(C1-C4)alkyl.
Suitable "(C2-C6)alkylidene" may include straight or branched one such as ethylidene, propylidene,
isopropylidene, butylidene, pentylidene, hexylidenε, and the like in which more preferred example may be
(C2-C4)alkylidene and the most preferred one may be ethylidene and butylidene.
Suitable "aryl(C1-C8)alkylidene" may include
aforementioned (C2-C6)alkylidene and methylene, which are substituted with aryl as mentioned below, wherein more preferred example may be phenyl(C1-C4)alkylidene and the most preferred one may be benzylidene.
Suitable "protected carboxy(C1-C8)alkylidene" may include aforementioned (C2-C6)alkylidene and methylene, which are substituted with protected carboxy as mentioned below, wherein more preferred example may be (C1-C4)alkoxycarbonyl(C1-C4)alkylidene and the most preferred one may be methoxycarbonylmethylene.
Suitable "leaving group" may include an acid residue and the like, and suitable examples of "acid residue" may be halogen (e.g. chlorine, bromine, iodine, etc.), sulfonyloxy (e.g. methanesulfonyloxy, benzenesulfonyloxy, toluenesulfonyloxy, etc.) or the like. Suitable "protected carboxy" may include esterified carboxy such as lower alkoxycarbonyl (e.g.
methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl,
isopropoxycarbonyl, butoxycarbonyl, tert-butoxycarbonyl, etc.), mono(or di or tri)phenyl(lower) alkoxycarbonyl which may have a nitro group (e.g. benzyloxycarbonyl,
4-nitrobenzyloxycarbonyl, phenethyloxycarbonyl,
benzhydryloxycarbonyl, trityloxycarbonyl, etc.), and the like, in which more preferred example may be C1-C4 alkoxycarbonyl and the most preferred one may be
methoxycarbonyl.
Suitable "aryl" may include phenyl, tolyl, xylyl, cumenyl, mesityl, naphthyl, and the like, in which the preferred example may be phenyl.
Suitable "halogen" may be chlorine bromine, fluorine and iodine, in which the preferred one may be chlorine and bromine. The processes for production of tricyclo compounds (I) of this invention are explained in detail in the following.
Process 1 :
The compound (Ia) or a salt thereof can be prepared by hydroxylating the compound ( II ) or a salt thereof.
The hydroxylating agent applicable to this process may be a conventional one which is capable of introducing hydroxy group(s) into the allyl moiety of starting
compound (II), for example, alkali metal permanganate (e.g. potassium permanganate, etc.), osmium tetroxide optionally in the presence of a suitable oxidizing agent to regenerate osmium tetroxide (e.g. N-methylmorpholine N-oxide, sodium chlorate, etc.), hydrogen peroxide, and the like.
This reaction is usually conducted in a conventional solvent which does not adversely influence the reaction such as water, methanol, ethanol, propanol, pyridine, ethyl acetate, N,N-dimethylformamide, dichloromethane, ethyl ether, isopropyl ether, 1,4-dioxane or a mixture thereof. The reaction temperature of this reaction is not critical and the reaction is usually conducted under from cooling to warming.
Process 2 :
The compound (lb) or a salt thereof can be prepared by oxidizing the compound (la) or a salt thereof to an aldehyde.
The oxidizing agent applicable to this process may be a conventional one which is capable of oxidizing vicinal diols to an aldehyde, for example, perhalogenic acid or a salt thereof (e.g. periodic acid, sodium metaperiodate, etc.), lead tetra(lower alkanoate) (e.g. lead
tetraacetate, etc.), and the like. This reaction is usually conducted in a conventional solvent which does not adversely influence the reaction such as water, methanol, ethanol, propanol, pyridine, ethyl acetate, N,N-dimethylformamide, dichloromethane, ethyl ether, isopropyl ether, 1,4-dioxane, or a mixture thereof.
The reaction temperature is not critical and the reaction is usually conducted under from cooling to warming.
Process 3 :
The compound (Ic) or a salt thereof can be prepared by reacting the compound (lb) or a salt thereof with the compound (IlIa) or (Illb).
In case that the compound (IlIa) is used in this reaction, this reaction can preferably be carried out in the presence of an organic or inorganic base such as lower alkylalkalimetal (e.g. methyllithium, butyllithium, etc.), alkali metal (e.g. lithium, sodium, potassium, etc.), alkaline earth metal (e.g. calcium, etc.), alkali metal hydride (e.g. sodium hydride, etc.), alkaline earth metal hydride (e.g. calcium hydride, etc.), alkali metal
hydroxide (e.g. sodium hydroxide, potassium hydroxide, etc.), alkali metal carbonate (e.g. sodium carbonate, potassium carbonate, etc.), alkali metal hydrogen
carbonate (e.g. sodium hydrogen carbonate, potassium hydrogen carbonate, etc.), alkali metal alkoxide (e.g. sodium methoxide, sodium ethoxide, potassium
tert-butoxide, etc.), alkali metal alkanoic acid (e.g. sodium acetate, etc.), trialkylamine (e.g. triethylamine, etc.), pyridine compound (e.g. pyridine, lutidine, picoline, 4-N,N-dimethylaminopyridine, etc.), guinoline, and the like. The reaction is usually conducted in a conventional solvent which does not adversely influence the reaction such as acetone, dichloromethane, alcohol (e.g. methanol, ethanol, etc.), tetrahydrofuran, pyridine, benzene,
N,N-dimethylformamide, hexane, ethyl ether, isopropyl ether, 1,4-dioxane, etc., or a mixture thereof.
The reaction temperature is not critical and the reaction is usually conducted under from cooling to warming.
Process 4 :
The compound (Id) or a salt thereof can be prepared by reducing the compound (Ic) or a salt thereof.
The reduction method applicable for this reaction is a conventional one which is capable of hydrogenating olefinic bond and may include, for example, reduction by using a combination of a metal (e.g. zinc, zinc amalgam, etc.) or a chrome compound (e.g. chromous chloride, chromous acetate, etc.) and an organic or inorganic acid (e.g. acetic acid, propϊonic acid, hydrochloric acid, sulfuric acid, etc.); and conventional catalytic reduction in the presence of a conventional metallic catalyst such as palladium catalysts (e.g. spongy palladium, palladium black, palladium oxide, palladium on carbon, colloidal palladium, palladium on barium sulfate, palladium on barium carbonate, palladium hydroxide on carbon, etc.), nickel catalysts (e.g. reduced nikel, nickel oxide, Raney nickel, etc.), platinum catalysts (e.g. platinum plate, spongy platinum, platinum black, colloidal platinum, platinum oxide, platinum wire, etc.); rhodium on alumina powder,, sodium borohydride, a combination of
tri(lower) alkylborane and sodium borohydride,
diisobutylaluminum hydride, and the like. This reaction is usually carried out in a
conventional solvent which does not adversely influence the reaction such as water, alcohol (e.g. methanol, ethanol, propanol, etc.), dioxane, tetrahydrofuran, acetic acid, buffer solution (e.g. phosphate buffer, acetate buffer, etc.), benzene, toluene, xylene, and the like, or a mixture thereof.
The reaction temperature is not critical and the reaction is usually carried out under from cooling to warming.
The object tricyclo compounds (I), obtained according to the processes as explained above can be isolated and purified in a conventional manner, for example,
extraction, precipitation, fractional crystallization, recrystallization, chromatography, and the like.
Suitable salts of the compounds (I), (la), (lb), (Ic), (Id) and (II) may include pharmaceutically
acceptable salts such as basic salts, for example, alkali metal salt (e.g. sodium salt, potassium salt, etc.), alkaline earth metal salt (e.g. calcium salt, magnesium salt, etc.), ammonium salt, amine salt (e.g. triethylamine salt, N-benzyl-N-methylamine salt, etc.) and other
conventional organic salts.
With respect to the tricyclo compounds (II) of this invention, it is to be understood that there may be one or more conformer(s) or stereoisomeric pairs such as optical and geometrical isomers due to asymmetric carbon atom(s) and double bond(s), and such isomers are also included within a scope of this invention.
The starting compound (II) in the process mentioned above contains known and novel compounds, and the known compounds are disclosed, for example, in European Patent Publication Nos. 184162 and 323042 and the new compound can be prepared by a conventional manner. PHARMACOLOGICAL ACTIVITIES OF THE TRICYCLO COMPOUNDS
The tricyclo compounds (I) possess pharmacological activities such as immunosuppressive activity,
antimicrobial activity, and the like, and therefore are useful for the treatment and prevention of immune-mediated diseases controlled by a immunosuppressant such as the resistance by transplantation of organs or tissue such as heart, kidney, liver, medulla ossium, skin, cornea, lung, pancreas, intestinum tenue, limb, muscle, nervus, etc.;
graft-versus-host diseases by medulla ossium
transplantation; autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's
thyroiditis, multiple sclerosis, myasthenia gravis, type I diabetes, and the like; and further infectious diseases caused by pathogenic microorganisms.
Further, the tricyclo compounds (I) are also useful for the treatment and the prophylaxis of inflammatory and hyperproliferative skin diseases and cutaneous
manifestations of immunologically-mediated illnesses, such as, psoriasis, atopical dermatitis, contact dermatitis and further eczematous dermatitises, seborrhoeis dermatitis, Lichen planus, Pemphigus; bullous Pemphigoid, Epidermolysis bullosa, urticaria, angioedemas, vasculitides, erythemas, cutaneous eόsinophilias, Lupus erythematosus, acne and Alopecia areata;
various eye diseases such as autoimmune diseases and so on (e.g. keratoconjunctivitis, vernal conjunctivitis, uveitis associated with Behcet's disease, keratitis, herpetic keratitis, conical cornea, dystrophia epithelialis corneae, corneal leukoma, ocular pemphigus, Mooren's ulcer,
Scleritis, Graves' ophthalmopathy, etc.);
reversible obstructive airways disease , which includes conditions such as asthma ( e.g. bronchial asthma, allergic asthma, intrinsic asthma, extrinsic asthma and dust asthma
), particularly chronic or inveterate asthma (e.g. late asthma and airway hyper-responsiveness), bronchitis and the like;
inflammation of mucosa and blood vessels such as gastric ulcers, vascular damage caused by ischemic diseases and thrombosis, ischemic bowel disease, inflammatory bowel disease, necrotizing enterocolitis, intestinal lesions associated with thermal burns, leukotriene B4-mediated diseases;
intestinal inflammations/allergies such as Coeliac disease, proctitis, eosnophilic gastroenteritis, mastocytosis,
Crohn's disease and ulcerative colitis;
food related allergic diseases which have symptomatic manifestation remote from the gastro-intestinal tract, for example migraine, rhinitis and eczema;
renal diseases selected from interstitial nephritis,
Goodpasture's syndrome, hemolytic-uremic syndrome and diabetic nephropathy;
nervous diseases selected from multiple myositis,
Guillain-Barre syndrome, Meniere's disease and
radiculopathy;
endocrine diseases selected from hyperthyroidism and
Basedow's disease;
hematic diseases selected from pure red cell aplasia, aplastic anemia, hypoplastic anemia, idiopathic
thrombocytopenic purpura, autoimmune hemolytic anemia, agranulocytosis and anerythroplasia;
bone diseases such as osteoporosis;
respiratory diseases selected from sarcoidosis, fibroid lung and idiopathic interstitial pneumonia; skin diseases selected from dermatomyositis, leukoderma vulgaris, ichthyosis vulgaris, photoallergic sensitivity and cutaneous T cell lymphoma;
circulatory diseases selected from arteriosclerosis, atherosclerosis, aortitis syndrome, polyarteritis nodosa and myocardosis;
collagen diseases selected from scleroderma, Wegener's granuloma and Sjogren's syndrome;
adiposis;
eosinophilic fasciitis;
periodontal disease;
nephrotic syndrome such as glomerulonephritis;
hemolytic-uremic syndrome;
photoallergic sensitivity;
male pattern alopecia or alopecia senilis; and so on.
And further, the tricyclo compounds (I) have liver regenerating activity and/or activities of stimulating hypertrophy and hyperplasia of hepatocytes. Therefore, they are useful for the treatment and prevention of hepatic diseases such as immunogenic diseases (e.g. chronic
autoimmune liver diseases selected from the group consistin of autoimmune hepatitis, primary biliary cirrhosis and sclerosing cholangitis), partial liver resection, acute liver necrosis (e.g. necrosis caused by toxins, viral hepatitis, shock or anoxia), B-virus hepatitis, non-A/non-B hepatitis and cirrhosis.
And further, the tricyclo compounds (I) are useful for various diseases because of its useful pharmaceutical activity such as augmenting activity of chemotherapeutic effect.
As examples for showing such pharmacological
activities, the pharmacological test data cf the tricyclo compounds (I) is illustrated in the following. Test 1
Suppression of in vitro Mixed Lymphocyte Reaction (MLR)
The MLR test was performed in microtiter plates, with each well containing 5 × 105 C57BL/6 responder cells
(H-2b), 5 × 105 mitomycin C treated (25 μg/ml mitomycin C at 37°C for 30 minutes and washed three times with RPMI
1640 medium) BALB/C stimulator cells (H-2b) in 0.2 ml RPMI
1640 medium supplemented with 10% fetal calf serum, 2mM sodium bicarbonate, penicillin (50 unit/ml) and
streptomycin (50 μg/ml). The cells were incubated at 37°C in humidified atmosphere of 5% carbon dioxide and 95% of air for 68 hours and pulsed with 3H-thymidine (0.5 μCi) 4 hours before the cells were collected. The object
compound of this invention were dissolved in ethanol and further diluted in RPMI 1640 medium and added to the cultures to give final concentrations of 100 nM or less.
The IC50 value (mol concentration to suppress 50% of MLR) was calculated by a conventional method, which is shown in the following Table 1.
The pharmaceutical composition of this invention can be used in the form of a pharmaceutical preparation, for example, in solid, semisolid or liquid form, which
contains the tricyclo compounds (I), as an active
ingredient, in admixture with an organic or inorganic carrier or excipient suitable for external, enteral or parenteral applications. The active ingredient may be compounded, for example, with the usual non-toxic,
pharmaceutically acceptable carriers for tablets, pellets, capsules, suppositories, solutions, emulsions,
suspensions, injections, ointments, liniments, eye drops lotion, gel, creme and any other form suitable for use. The carriers which can be used are water, glucose,
lactose, gum acacia, gelatin, mannitoi, starch paste, magnesium trisilicate, talc, corn starch, keratin,
colloidal silica, potato starch, urea and other carriers suitable for use in manufacturing preparations, in solid, semisolid, or liquid form, and in addition auxiliary, stabilizing, thickening, solubilizing and coloring agents and perfumes may be used. Particularly, as a solubilizing agent, there may be exemplified water-soluble cellulose polymer (i.e. hydroxypropyl methylcellulose, etc.), water-soluble glycol (i.e. propylene glycol, etc.), etc. The active object compound is included in the
pharmaceutical composition in an amount, sufficient to produce the desired effect upon the process or condition of diseases.
For applying this composition to human, it is
preferable to apply it by parenteral or entεral
administration. While the dosage of therapeuticaliy effective amount of the tricyclo compound (I) varies from and also depends upon the age and condition of each individual patient to be treated, a daily dose of about 0.01-1000 mg, preferably 0.1-500 mg and more preferably 0.5-100 mg, of the active ingredient is generally given for treating diseases, and an average single dose of about 0.5 mg, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg, 250 mg and 500 mg is generally administered. The following examples are given for the purpose of illustrating the present invention. Example 1
A solution of 17-Allyl-1-hydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo- [22.3.1.04,9]octacos-18-ene-2,3,10,16-tetraone (2.57 g) in a mixture of 1,4-dioxane (40 ml) and water (4 ml) was treated with catalytic amount of osmium tetroxide in tetrahydrofuran and 4-methylmorpholine N-oxide (1.15 g), and stirring was continued for 5.5 hours at room
temperature. To this reaction mixture was added water, and the separated aqueous phase was extracted with diethyl ether. The combined organic layers were washed with water and brine, dried over magnesium sulfate and concentrated. The residue was purified by silica gel column
chromatography to give pure 1-hγdroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylvinyl]-17-(2,3-dihydroxypropyl)-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene- 2,3,10,16-tetraone (1.91 g).
FAB MS : m/z 844 (M + Na)
Example 2
To a solution of 1-hydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylvinγl]-17-(2,3-dihγdroxγpropyl)-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.04'9]octacos-18-ene-2,3,10,16-tetraone (220 mg) in 1,4-dioxane (7 ml) was added a solution of sodium metaperiodate (573 mg) in water (2 ml) at 0°C. After 1 hour at the same temperature, diethyl ether and water was added, and the separated aqueous phase was extracted with diethyl ether. The, combined organic layers were washed with brine, dried over magnesium sulfate, and concentrated in vacuo to give
17-formylmethγl-1-hydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methγlvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4- azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetraone
(220 mg). This product was used to the next reaction without further purification.
1H NMR (CDCl3) : 9.70-9.78 (1H, m)
Example 3-1)
To a stirred suspension of
n-butyltriphenγlphosphonium bromide (505 mg) in diethyl ether (9.2 ml) at 0°C was added 1.4 M methyllithium in hexane (0.9 ml). The orange reaction mixture was warmed to room temperature and stirred for 2 hours. To a
solution of 17-formylmethyl-1-hydroxγ-12-[2-(4-hydroxy- 3-methoxycyclohexyl)-1-methylvinyl]-23,25-dimethoxy13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo- [22.3.1.04'9]octacos-18-ene-2,3,10,16-tetraone (150 mg) in diethyl ether (10 ml) was added the above obtained 0.13 M wittig reagent at 0°C and warmed to room temperature over 2 hours. The reaction mixture was washed with water and brine, and dried over magnesium sulfate. After
evaporation, the residue was purified by silica gel column chromatography followed by chromatography on thin layer chromatography-grade silica gel to give 17-(2-hexenyl)-1- hydroxy-12-[2-(4-hydroxy-3-methoxycyclohexy1)-1- methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl- 11,28-dioxa-4-azatricyclo[22.3.1.04'9]octacos-18-ene- 2,3,10,16-tetraone (38 mg).
FAB MS : m/z 852 (M + Na)
Example 3-2)
To a cold (0°C), magnetically stirred slurry of benzyltriphenylphosphonium chloride (650 mg) in diethyl ether (10 ml) was added dropwise methyllithium (1.2 ml of 1.4 M in tetrahydrofuran). This ylide solution was allowed to warm to room temperature. A solution of
17-formylmethyl-l-hydroxy-12-[2-(4-hydroxy-3- methoxycyclohexyl)-1-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatircyclo- [22.3.1.04,9]octacos-18-ene-2,3,10,16-tetraone (150 mg) in diethyl ether (15 ml) was treated with recooled above ylide solution (1.9 ml) at 0°C. The reaction mixture was warmed to room temperature and stirred for one hour. The mixture was quenched with water and diethyl ether was added thereto. The organic layer was washed with water and brine, dried over magnesium sulfate, and concentrated. The residue was subjected to a chromatography on silica gel (TLC grade) eluting with 70% ethyl acetate in n-hexane to give 1-hydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-17- (3-phenyl-2-propenyl)-11,28-dioxa-4-azatricyclo- [22.3.1.04,9]octacos-18-ene-2,3,10,16-tetraone (70 mg).
FAB MS : m/z 886 (M + Na)
Example 4-1)
A solution of 17-(2-hexenyl)-l-hydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylvinyl]-23,25-dimethoxy-13,19.,21,.27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.04'9]octacos-18-ene-2,3,10,16-tetraone
(32 mg) in ethanol (2 ml) was admixed with Rhodium on alumina powder (10 mg) and stirred for 3.3 hours under atmospheric pressure of hydrogen. The catalyst was separated by filtration through Celite. Concentration of this filtrate gave 17-hexyl-1-hydroxy-12-[2-(4-hydroxy- 3-methoxycyclohexyl)-1-methylvinyl]-23,25-dimethoxy- 13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo- [22.3.1.04,9]octacos-18-ene-2,3,10,16-tetraone (25 mg).
FAB MS : m/z 827 (M + Na)
Example 4-2)
1-Hydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)- 1-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl- 17- [3- (phenyl)propyl]-11,28-dioxa-4-azatricyclo-[22.3.1.0 4,9]octacos-18-ene-2,3,10,16-tetraone was
obtained in 57.6% yield in substantially the same manner as that of Example 4-1).
FAB MS : m/z 888 (M + Na)
Example 5
17-(2-Butenyl)-1-hydroxy-12-[2-(4-hydroxy-3-methoxy-cyclohexyl)-1-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos- 18-ene-2,3,10,16-tetraone was obtained in 22.5% yield in substantially the same manner as those of Examples 2 and
3-1) by using butyllithium instead of methyllithium.
FAB MS : m/z 824 (M + Na)
Example 6
17-Butyl-1-hydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylvinyl]-23,25-dimethoxy-13,19,21,27- tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.04'9]octacos- 18-ene-2,3,10,16-tetraone was obtained in 80.8% yield in substantially the same manner as that of Example 4-1).
FAB MS : m/z 827 (M + Na)
Example 7
A solution of 17-allyl-1,14-dihydroxy-12-[2-(4- hydroxy-3-methoxycyclohexyl)-1-methylvinyl]-23,25- dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4- azatricyclo[22.3.1.0 ' ]octacos-18-ene-2,3,10,16- tetraone (2.0 g) in tetrahydrofuran (30 ml) and water (1 ml) was treated with catalytic amount of osmium
tetroxide in tetrahydrofuran and 4-methylmorpholine
N-oxide (873 mg) and stirring was continued for 2 hours at room temperature. Then 4-methylmorpholine N-oxide (583 mg) was added and this mixture was stirred for additional 4 hours at the same temperature. To this reaction mixture wda added diethyl ether and water, and the separated aqueous phase was extracted with diethyl ether. The combined organic layer was washed in turn with water and brine, dried over magnesium sulfate and concentrated. The residue was purified by silica gel column chromatography (elution with ethyl acetate) to give pure
1,14-dihydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylvinyl]-17-(2,3-dihydroxypropyl)-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetraone (1.4 g) .
FAB MS : m/z 860 (M + Na)
Example 8
17-Formylmethyl-1,14-dihydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylvinyl]-23,25-dimethoxy- 13, 19, 21, 27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetraone was
obtained in quantitative yield in substantially the same manner as that of Example 2.
1H NMR (CDCl3, δ) : 9.70-9.78 (1H, m)
Example 9
17-(2-Butenyl)-1,14-dihydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo- [22.3.1.04,9]octacos-18-ene-2,3,10,16-tetraone was
obtained in 2.4% yield in substantially the same manner as that of Example 3-1).
FAB MS : m/z 840 (M + Na)
Example 10-1)
1,14-Dihydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylvinyl]-23,25-dimethoxy-13,19,21,27-tεtramethyl-17- ( 3-phenyl-2-propenyl)-11,28-dioxa-4-azatricyclo- [22.3.1.04,9]octacos-18-ene-2,3,10,16-tetraone was obtained in 73.1% yield in substantially the same manner as those of Examples 2 and 3-2).
FAB MS : m/z 902 (M + Na) Example 10-2)
To a solution of l,14-dihydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylvinyl]-17-(2,3-dihydroxypropyl)-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetraone (100 mg) in benzene (5 ml) was added lead tetraacetate (53 mg). The mixture was stirred at room temperature for 1 hour. Methyl (triphenyl-phosphoranylidene) acetate (120 mg) was added thereto and the stirring was continued for additional 16 hours.
Diethyl ether and water were added threto and the organic layer was separated. The organic phase was washed with brine, dried over magnesium sulfate and concentrated. The residue was subjected to a silica gel column
chromatography eluting with diethyl ether to give
1,14-dihydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1- methylvinyl]-23,25-dimethoxy-17-(3-methoxycarbonyl-2- propenyl)-13,19,21,27-tetramethyl-11,28-dioxa-4- azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetraone
(140 mg).
FAB MS : m/z 884 (M + Na).
Example 11-1)
1,14-Dihydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)- 1-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-17- [3-(phenyl)propyl]-11,28-dioxa-4-azatricyclo[22.3.1.04,9]- octacos-18-ene-2,3,10,16-tetraone was obtained in 40.2% yield in substantially the same manner as that of Example 4-1).
FAB MS : m/z 904 (M + Na) Example 11-2)
A solution of 1,14-dihydroxγ-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylvinyl]-23,25-dimethoxy-17- (3-methoxycarbonyl-2-propenyl)-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-one- 2,3,10,16-tetraone (120 mg) in methanol (3 ml) was admixed with platinum oxide and stirred for one hour under
atmospheric pressure of hydrogen. The catalyst was separated by filtration through Celite. The filtrate was concentrated, and the residue was purified by thin layer chromatography to give l,14-dihydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylvinyl]-23,25-dimethoxy-17-[3- (methoxycarbonyl)propyl]-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetraone (10 mg).
FAB MS : m/z 886 (M + Na)

Claims

CLAIMS :
A compound of the formula
wherein R1 is hydrogen or acyl,
R2 is hydrogen, hydroxy, alkoxy or acyloxy, R3 is (C3-C7) alkyl, aryl(C2-C7) alkyl,
protected carboxy(C2-C7) alkyl,
1-(C3-C7) alkenyl, aryl-1-(C2-C7 )alkenyl or protected carboxy-1-(C2-C7) alkenyl, R4 is hydroxy or alkoxy,
R5 is hydrogen and R6 is hydroxy or methoxy, or
R5 and R 6 are combined to form oxo,
A is methylene, hydroxymethylene or
carbonyl,
n is an integer of 1 or 2, and the symbol of a line and dotted line is
single bond or a double bond,
or a pharmaceutically acceptable salt thereof. A process for the preparation of a compound of the formula :
wherein R1 is hydrogen or acyl,
R2 is hydrogen, hydroxy, alkoxy or acyloxy,
R3 is (C3-C7)alkyl, aryl(C2-C7)alkyl, protected carboxy(C2-C7)alkyl,
1-(C3-C7)alkenyl, aryl-1-(C2-C7)alkenyl or protected carboxy-1-(C2-C7)alkenyl,
R4 is hydroxy or alkoxy,
R5 is hydrogen and R6 is hydroxy or methoxy, or
R5 and R6 are combined to form oxo,
A is methylene, hydroxymethylene or
carbonyl,
n is an integer of 1 or 2, and
the symbol of a line and dotted line is a
single bond or a double bond,
or a salt thereof, which comprises (a) reacting a compound of the formula
wherein R1, R2, R4, R5, R6, A, n and the symbol of a line and dotted line are each as defined above,
or a salt thereof, with a compound of the formula :
or
(R8)3P=CH-R9 (IIIb) wherein R7 is (C2-C6)alkyl, aryl(C1-C6) alkyl or
protected carboxy(C1-C6) alkyl,
R8 is aryl,
R9 is protected carboxy, and
X is halogen, to give a compound of the formula :
wherein R1, R2, R4, R5, R6, A,n and the symbol of a line and dotted line are each as defined above, and
R10 is (C2-C6)alkylidene, aryl(C1-C6)- alkylidene or protected carboxy(C1-C6)alkylidene,
or a salt thereof; or
(b) reducing a compound of the formula
wherein R1, R2, R4, R5, R5, R10, A, n and the symbol of a line and dotted line are each as defined above,
or a salt thereof, to give a compound of the formula:
wherein R1, R2, R4, R5, R6, R7, A, n and the symbol of a line and dotted line are each as defined above,
or a salt thereof. 3. A pharamaceut ion containing tricyclo
compoun of claim 1, as an active ingredient, in association with a pharmaceutically acceptable, substantially non-toxic carrier or excipient.
4. A use of tricyclo compounds of claim 1 as a
medicamen.
5. A method for treating or preventing resistance by
transplantation, graft-versus-host diseases by medulla ossium, autoimmune diseases and infectious diseases which comprises administering a compound of claim 1 to human or animal. 6. A tricyclo compounds of Claim 1 for use as a
medicament.
7. A use of a tricyclo compound of Claim 1 for
manufacturing a medicament, for treating or preventing resistance by transplantation, graft-versus-host diseases by medulla ossium, autoimmune diseases and infectious diseases.
8. A process for preparing a pharmaceutical composition which comprises admixing a tricyclo compound of Claim
1 with a pharmaceutically acceptable carrier or excipient.
EP91911075A 1990-06-25 1991-06-18 Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same Withdrawn EP0536401A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9014136 1990-06-25
GB909014136A GB9014136D0 (en) 1990-06-25 1990-06-25 Tricyclo compounds,a process for their production and a pharmaceutical composition containing the same

Publications (1)

Publication Number Publication Date
EP0536401A1 true EP0536401A1 (en) 1993-04-14

Family

ID=10678180

Family Applications (1)

Application Number Title Priority Date Filing Date
EP91911075A Withdrawn EP0536401A1 (en) 1990-06-25 1991-06-18 Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same

Country Status (4)

Country Link
EP (1) EP0536401A1 (en)
JP (1) JPH06501920A (en)
GB (1) GB9014136D0 (en)
WO (1) WO1992000313A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6485807B1 (en) 1997-02-13 2002-11-26 Samsung Electronics Co., Ltd. Silicon wafers having controlled distribution of defects, and methods of preparing the same
US6503594B2 (en) 1997-02-13 2003-01-07 Samsung Electronics Co., Ltd. Silicon wafers having controlled distribution of defects and slip

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565560A (en) * 1991-05-13 1996-10-15 Merck & Co., Inc. O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
US5262533A (en) * 1991-05-13 1993-11-16 Merck & Co., Inc. Amino O-aryl macrolides having immunosuppressive activity
US5708002A (en) * 1991-09-05 1998-01-13 Abbott Laboratories Macrocyclic immunomodulators
CA2103454C (en) * 1991-09-05 2004-11-02 Jay R. Luly Macrocyclic immunomodulators
US5247076A (en) * 1991-09-09 1993-09-21 Merck & Co., Inc. Imidazolidyl macrolides having immunosuppressive activity
US5252732A (en) * 1991-09-09 1993-10-12 Merck & Co., Inc. D-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity
US5284840A (en) * 1992-06-12 1994-02-08 Merck & Co., Inc. Alkylidene macrolides having immunosuppressive activity
US5284877A (en) * 1992-06-12 1994-02-08 Merck & Co., Inc. Alkyl and alkenyl macrolides having immunosuppressive activity
US5496831A (en) * 1994-05-13 1996-03-05 The General Hospital Corporation Inhibition of insulin-induced adiposis
US5880280A (en) * 1994-06-15 1999-03-09 Merck & Co., Inc. Aryl, alkyl, alkenyl and alkynylmacrolides having immunosuppressive activity
US5693648A (en) * 1994-09-30 1997-12-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides having immunosuppressive activity
US7186518B2 (en) * 2003-11-21 2007-03-06 Dade Behring Inc. Method and composition useful for determining FK 506
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
MX2019005504A (en) * 2016-11-10 2019-08-12 Novartis Ag Bmp potentiators.
AU2020211994A1 (en) * 2019-01-23 2021-08-12 The Johns Hopkins University Non-immunosuppressive FK506 analogs and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
JP2799208B2 (en) * 1987-12-09 1998-09-17 フアイソンズ・ピーエルシー Macrocyclic compound

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9200313A1 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6485807B1 (en) 1997-02-13 2002-11-26 Samsung Electronics Co., Ltd. Silicon wafers having controlled distribution of defects, and methods of preparing the same
US6503594B2 (en) 1997-02-13 2003-01-07 Samsung Electronics Co., Ltd. Silicon wafers having controlled distribution of defects and slip
US6676753B2 (en) 1997-02-13 2004-01-13 Samsung Electronics Co., Ltd. Czochralski pullers for manufacturing monocrystalline silicon ingots, including heat shield having sloped portions
US6780238B2 (en) 1997-02-13 2004-08-24 Samsung Electronics Co., Ltd. Argon/ammonia rapid thermal annealing for silicon wafers

Also Published As

Publication number Publication date
GB9014136D0 (en) 1990-08-15
JPH06501920A (en) 1994-03-03
WO1992000313A1 (en) 1992-01-09

Similar Documents

Publication Publication Date Title
EP0536401A1 (en) Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
KR930010706B1 (en) Tricyclo compound and preparation thereof
US5221740A (en) Oxepane isomers of rapamycin useful as immunosuppressive agents
US5284840A (en) Alkylidene macrolides having immunosuppressive activity
US5344925A (en) Imidazolidyl macrolides having immunosuppressive activity
EP0642516B1 (en) Macrocyclic immunomodulators
WO1991013899A1 (en) Tricyclo compounds
SK26094A3 (en) O-heteroaryl-, o-alkylheteroaryl-, o-alkenylheteroaryl- and o-alkylheteroaryl macrolides compounds, the method of their production and pharmaceutical preparations containing those
EP0532089A1 (en) N-heteroaryl, N-alkylheteroaryl, N-alkenylheteroaryl & N-alkynylheteroarylmacrolides
EP0445975A1 (en) New hydroxymacrolide derivatives having immunosuppressive activity
GB2267707A (en) Alkyl and alkenyl macrolides having immunosuppressive activity
US5493019A (en) Tetrahydropyran derivatives
US5384316A (en) 4,16-diazatetracyclo[23.3.1.1.Hu 14,17=b . 0 Hu 4,9 triaconta-16,19-diene-2,3,10-trione derivatives
EP0463690A1 (en) Antagonists of immunosuppressive macrolides
AU2825495A (en) Aryl, alkyl, alkenyl, and alkynylmacrolides
US6121257A (en) Sulfamate containing macrocyclic immunomodulators
WO1992000980A1 (en) Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
GB2244991A (en) Tricyclo compounds
WO1992013862A1 (en) Lactone compounds
JP2563080B2 (en) Sugar derivative of macrolide
WO1992000314A1 (en) Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
CA2040551A1 (en) Deoxymacrolide derivatives having immunosuppressive activity
GB2246568A (en) Tricyclo compound, a process for its production and a pharmaceutical composition containing the same
GB2249787A (en) Lactone compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930108

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): CH DE FR GB IT LI

17Q First examination report despatched

Effective date: 19930730

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19940210